National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 2) (PB 18 of 2017) (Cth)

PB 18 of 2017

National Health Determination under paragraph 98C(1)(b) Amendment 2017
(No. 2)

_____________________________________________________________________

I, LOUISE CLARKE, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated 30^th March 2017

LOUISE CLARKE

First Assistant Secretary (Acting)

Pharmaceutical Benefits Division

Department of Health

1              Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 2).

(2)This Instrument may also be cited as PB 18 of 2017.

2              Commencement  

This instrument commences on 1 April 2017.

3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1            Amendments

1. Schedule 4, after entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g

insert in the column headed “Form (strength, type, size, etc.)”:

Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g

1. Schedule 4, after entry for Electrolyte Replacement, Oral

insert:

Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL
Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL

1. Schedule 4, after entry for Salbutamol in the form Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation)

insert in the column headed “Form (strength, type, size, etc.)”:

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20